My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Envafolimab Biosimilar, PD-L1 Monoclonal Antibody

Envafolimab Biosimilar, PD-L1 Monoclonal Antibody

KN035, KN035-Fc, VHH-Fc Fusion Protein, PD-L1 Nanobody

Catalog No. Product Name Size List Price (US$) Quantity
C072P Envafolimab Biosimilar, PD-L1 Monoclonal Antibody 1 mg 250.00
C072P Envafolimab Biosimilar, PD-L1 Monoclonal Antibody 5 mg 750.00
C072P Envafolimab Biosimilar, PD-L1 Monoclonal Antibody 20 mg 2000.00
Description

C072P: Envafolimab Biosimilar, PD-L1 Monoclonal Antibody

Recombinant humanized nanobody (VHH-hIgG1 Fc fusion protein).
Isotype: Human IgG1 Fc.
Source: The anti-human programmed cell death ligand 1 (PD-L1) nanobody envafolimab biosimilar was produced in the envafolimab CHO stable cell line.
Specificity/Sensitivity: The in vivo grade envafolimab biosimilar specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by envafolimab.
Form of Antibody: 0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade envafolimab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is envafolimab biosimilar research grade? Envafolimab is a humanized nanobody (VHH-hIgG1 Fc fusion protein) directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Envafolimab biosimilar uses the same protein sequences as the therapeutic antibody envafolimab.

PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Envafolimab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Syd Labs also provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody

PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs also provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Related Links

See our Privacy Policy